IMVT vs VRDN
IMVT: Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases. VRDN: A biopharmaceutical company commercializing therapies for thyroid eye disease and developing a pipeline of treatments for autoimmune and rare diseases.
Side-by-side fundamentals
| Metric | IMVT | VRDN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $30.26 | $18.34 | |
| Market cap as of 2026-08-03 (share count; price 2026-10-08) | $6.3B | $2.1B | |
| ROE | -59.3% | -47.4% | VRDN higher |
| ROA | -52.8% | -38.1% | VRDN higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.54 | IMVT lower |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.5% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.20 | 1.06 | |
| 1-year return as of 2026-10-08 close | +88.2% | -14.1% | IMVT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.